

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) are hyperlinks to full guidance	Titles	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
				Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2013-14					
Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)	21/03/2014	Rituximab in combination with glucocorticoids - for treating anti-neutrophil cytoplasmic antibody-associated vasculitis	Yes		
Colorectal cancer (metastatic) - afibercept (TA307)	21/03/2014	Afivercept in combination with irinotecan and fluorouracil-based therapy - for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	No	Not recommended	
Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)	24/02/2014	Pixantrone monotherapy - for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma	Yes		
Macular oedema (central retinal vein occlusion) - afibercept solution for injection (TA305)	24/02/2014	Afivercept - for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion	Yes		
End-stage arthritis of the hip - Total hip replacement and resurfacing arthroplasty (TA304)	26/02/2014	Total hip replacement and resurfacing arthroplasty - for end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44)	N/A	Does not affect formulary	
Multiple sclerosis (relapsing) - teriflunomide (TA303)	23/01/2014	Teriflunomide - for treating relapsing-remitting multiple sclerosis	Yes		
Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) (TA302)	27/11/2013	Canakinumab - for treating systemic juvenile idiopathic arthritis (terminated appraisal)	No	Unable to recommend	
Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)	27/11/2013	Fluocinolone acetonide intravitreal implant - for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology)	Yes		
Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300)	27/11/2013	Peginterferon alfa and ribavirin - for treating chronic hepatitis C in children and young people	No	Not applicable to C&W	
Leukaemia (chronic myeloid) - bosutinib (TA299)	27/11/2013	Bosutinib - not recommended for previously treated chronic myeloid leukaemia	No	Not recommended	
Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)	27/11/2013	Ranibizumab - for treating choroidal neovascularisation associated with pathological myopia	Yes		
Vitreomacular traction - ocriplasmin (TA297)	29/10/2013	Ocriplasmin - for treating vitreomacular traction	Yes		
Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296)	25/09/2013	Crizotinib - for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene	No	Not recommended	

Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295)	28/08/2013	Everolimus - in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy	No	Not applicable to C&W
Macular degeneration (wet age-related) - afibercept (TA294)	24/07/2013	Aflibercept - solution for injection for treating wet age-related macular degeneration	Yes	
Thrombocytopenic purpura - eltrombopag (TA293)	24/07/2013	Eltrombopag - for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)	Yes	
Bipolar disorder (adolescents) - aripiprazole (TA292)	24/07/2013	Aripiprazole - for treating moderate to severe manic episodes in adolescents with bipolar I disorder	No	Not applicable to C&W
Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291)	26/06/2013	Pegloticase - for treating severe debilitating chronic tophaceous gout	No	Not recommended
Overactive bladder - mirabegron (TA290)	26/06/2013	Mirabegron - for treating symptoms of overactive bladder	Yes	
Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289)	26/06/2013	Ruxolitinib - for disease related splenomegaly or symptoms in adults with myelofibrosis	No	Not recommended
Type 2 Diabetes - Dapagliflozin combination therapy (TA288)	25/06/2013	Dapagliflozin - given with other drugs as a possible treatment for some people with type 2 diabetes	Yes	
Pulmonary embolism and recurrent venous thromboembolism - Rivaroxaban (TA287)	25/06/2013	Rivaroxaban - as a possible treatment for adults with pulmonary embolism and to prevent a further deep vein thrombosis or pulmonary embolism.	Yes	
Schizophrenia or bipolar disorder - Loxapine inhalation (TA286)	24/05/2013	Loxapine - unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder because no evidence submission was	No	Unable to recommend
Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced platinum-sensitive or partially platinum sensitive) - Bevacizumab (TA285)	21/05/2013	Bevacizumab - not recommended given with gemcitabine and carboplatin for treating adults with the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube or primary peritoneal cancer) that has not been previously treated with	No	Not recommended
Bevacizumab in combination with paclitaxel and carboplatin for first-time treatment of a ovarian cancer (TA284)	21/05/2013	Bevacizumab - not recommended given with paclitaxel and carboplatin, as first-line treatment for advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).	No	Not recommended
Macular oedema (retinal vein occlusion) - Ranibizumab (TA283)	21/05/2013	Ranibizumab - as a possible treatment for some people who have sight problems because of macular oedema caused by retinal vein occlusion	Yes	

Idiopathic pulmonary fibrosis - Pirfenidone (TA282)	19/04/2013	Pirfenidone - as a possible treatment for some people with idiopathic pulmonary fibrosis	No	Not applicable to C&W
Gout - Canakinumab (TA281)	22/04/2013	Canakinumab - unable to recommend NHS use. TA terminated due to lack of evidence submission.	No	Unable to recommend
Rheumatoid arthritis - Abatacept (2nd line) (TA280)	19/04/2013	Abatacept - recommended for patients not responding sufficiently to beta interferon.	Yes	
Vertebral fractures - Vertebroplasty and Kyphoplasty (TA279)	22/04/2013	Vertebroplasty and kyphoplasty (without stenting) - possible treatment options for some people with spinal compression fractures caused by osteoporosis	No	Not applicable to C&W
Asthma (Severe, persistent. Patient aged 6+, adults) - Omalizumab (TA278)	22/04/2013	Omalizumab - possible additional treatment to standard asthma therapy for some people aged 6 years and over with severe persistent allergic asthma	No	Not applicable to C&W